{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Squamous+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&page=7", "query": { "condition": "Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 721, "total_pages": 73, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Squamous+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Squamous+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T15:48:57.751Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04619797", "title": "A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Tiragolumab Matching Placebo", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 542, "start_date": "2020-12-15", "completion_date": "2025-11-20", "has_results": true, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-11T15:48:57.751Z", "location_count": 11, "location_summary": "Los Angeles, California • Whittier, California • Fort Myers, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Winter Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04619797" }, { "nct_id": "NCT03965689", "title": "Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Lung Non-Small Cell Squamous Carcinoma", "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Lung Non-Squamous Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-04-16", "completion_date": "2027-03-20", "has_results": true, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-11T15:48:57.751Z", "location_count": 10, "location_summary": "Los Angeles, California • Newport Beach, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03965689" }, { "nct_id": "NCT04524689", "title": "Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)" ], "interventions": [ { "name": "SAR408701 (Tusamitamab ravtansine)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2020-10-26", "completion_date": "2024-12-24", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-11T15:48:57.751Z", "location_count": 1, "location_summary": "Westwood, Kansas", "locations": [ { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04524689" }, { "nct_id": "NCT02309892", "title": "A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "L-DOS47", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helix BioPharma Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2015-04-20", "completion_date": "2019-09-20", "has_results": true, "last_update_posted_date": "2024-06-03", "last_synced_at": "2026-10-11T15:48:57.751Z", "location_count": 2, "location_summary": "Cleveland, Ohio • Houston, Texas", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02309892" }, { "nct_id": "NCT01294306", "title": "MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenosquamous Lung Carcinoma", "Bronchioloalveolar Carcinoma", "Large Cell Lung Carcinoma", "Lung Adenocarcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "Squamous Cell Lung Carcinoma" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2011-02", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-10-11T15:48:57.751Z", "location_count": 7, "location_summary": "Beverly Hills, California • Duarte, California • Los Angeles, California + 4 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01294306" }, { "nct_id": "NCT02831933", "title": "Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Squamous Cell Carcinoma Stage IV", "Nonsquamous Nonsmall Cell Neoplasm of Lung", "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "ADV/HSV-tk", "type": "BIOLOGICAL" }, { "name": "Valacyclovir", "type": "DRUG" }, { "name": "SBRT", "type": "RADIATION" }, { "name": "nivolumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Eric Bernicker, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2017-02-15", "completion_date": "2020-11-05", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-11T15:48:57.751Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02831933" }, { "nct_id": "NCT06561386", "title": "A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2024-10-07", "completion_date": "2032-08-04", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-11T15:48:57.751Z", "location_count": 56, "location_summary": "Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 52 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06561386" }, { "nct_id": "NCT07246863", "title": "Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Non-Squamous Non-Small Cell Lung Cancer", "Adult Solid Tumor" ], "interventions": [ { "name": "Visugromab RDE (recommended dose for expansion)", "type": "BIOLOGICAL" }, { "name": "Visugromab 6mg/kg", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Placebo Saline Infusion", "type": "OTHER" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "CatalYm GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2025-10-07", "completion_date": "2031-10-01", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-11T15:48:57.751Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mineola", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07246863" }, { "nct_id": "NCT02193282", "title": "Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IB Lung Non-Small Cell Carcinoma AJCC v7", "Stage II Lung Non-Small Cell Cancer AJCC v7", "Stage IIA Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIB Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Clinical Observation", "type": "OTHER" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 390, "start_date": "2015-02-11", "completion_date": "2027-02-03", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-11T15:48:57.751Z", "location_count": 1403, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 888 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02193282" }, { "nct_id": "NCT07085091", "title": "A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NSCLC (Advanced Non-small Cell Lung Cancer)", "HNSCC", "CRC (Colorectal Cancer)", "ESCC", "Colo-rectal Cancer", "Head and Neck Cancer", "Esophageal Squamous Cell Carcinoma (ESCC)" ], "interventions": [ { "name": "ALX2004", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ALX Oncology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2025-08-18", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-11T15:48:57.751Z", "location_count": 12, "location_summary": "La Jolla, California • Santa Monica, California • Tampa, Florida + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07085091" } ] }